SCHEMBL2116124

SCHEMBL2116124

Cc1cccc2cc(CNc3ncnc4ccnn34)c(N3CCNC(=O)C3)nc12

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 19/20 0.45
EED O75530 1/20 0.40
SUZ12 Q15022 1/20 0.40
EZH2 Q15910 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117093 0.88 PIK3CD (0.46) PIK3CDEEDSUZ12EZH2
SCHEMBL2115921 0.88 PIK3CD (0.45) PIK3CDEEDSUZ12EZH2
SCHEMBL2115441 0.86 PIK3CD (0.41) PIK3CDEEDSUZ12EZH2
SCHEMBL713702 0.82 PIK3CD (0.53) PIK3CD
SCHEMBL17530807 0.78 PIK3CD (0.58) PIK3CD
SCHEMBL716993 0.78 PIK3CD (0.50) PIK3CD
SCHEMBL716764 0.76 PIK3CD (0.48) PIK3CD
SCHEMBL713514 0.76 PIK3CD (0.48) PIK3CD
SCHEMBL2113787 0.76 SOS1 (0.34) PIK3CD
SCHEMBL2113779 0.76 SOS1 (0.34) PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US claimed
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA PIK3CD 6/4885EED 4012/4885SUZ12 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.